Form 4 for NBIX NEUROCRINE BIOSCIENCES INC
Accepted 2026-01-20 00:00:00 ET · period of report 2026-01-16 · accession 0001567160-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-01-20 | 2026-01-16 | NBIX | Gano Kyle | CEO, Dir | S - Sale+OE | $132.70 | -36.4K | 140.4K | -21% | -$4.83M |
| DM | 2026-01-20 | 2026-01-16 | NBIX | Gano Kyle | CEO, Dir | M - OptEx | $35.99 | +36.4K | 175.0K | +26% | +$1.31M |
| DM | 2026-01-20 | 2026-01-16 | NBIX | Gano Kyle | CEO, Dir | M - OptEx | $0.00 | -36.4K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-16 | S | D | 1,812 | $132.71 | 140,407 | D | — | — | (F3) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $131.49 to $133.79. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range |
| 2 | Common | Common Stock | 2026-01-16 | M | A | 1,812 | $35.99 | 142,219 | D | — | — | |
| 3 | Common | Common Stock | 2026-01-16 | M | A | 34,588 | $35.99 | 174,995 | D | — | — | |
| 4 | Common | Common Stock | 2026-01-16 | S | D | 34,588 | $132.70 | 140,407 | D | — | — | (F2) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $131.42 to $133.98. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range |
| 5 | Derivative | Incentive Stock Option | 2026-01-16 | M | D | 1,812 | $0.00 | 0 | D | $35.99 · — to 2026-02-05 | 1,812 Common Stock | (F4) The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning on March 5, 2016. These options were due to expire on February 5, 2026. |
| 6 | Derivative | Non-Qualified Stock Option | 2026-01-16 | M | D | 34,588 | $0.00 | 0 | D | $35.99 · — to 2026-02-05 | 34,588 Common Stock | (F4) The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning on March 5, 2016. These options were due to expire on February 5, 2026. |